Industry
Medical - Devices
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Loading...
Open
75.70
Mkt cap
30B
Volume
1.4M
High
76.61
P/E Ratio
45.90
52-wk high
142.00
Low
74.78
Div yield
N/A
52-wk low
62.34
Portfolio Pulse from Benzinga Newsdesk
April 25, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
April 25, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Insights
April 17, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 3:22 pm
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 6:10 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 3:42 pm
Portfolio Pulse from Avi Kapoor
April 01, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
March 25, 2024 | 6:30 pm
Portfolio Pulse from Benzinga Insights
March 20, 2024 | 6:45 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.